Seaport Therapeutics Additional Phase 1 Data Validates the Glyph Platform

Seaport Therapeutics (SPTX) released positive Phase 1 data for its GlyphAgo platform, demonstrating successful bypass of first-pass liver metabolism. The findings support upcoming Phase 2 studies in generalized anxiety disorder (GAD).

Key Takeaways

• 1.SPTX reported positive Ph1 multiple-ascending dose data for GlyphAgo, validating the Glyph platform's ability to bypass first-pass liver metabolism.
• 2.New data supports the initiation of two parallel Ph2 studies for GlyphAgo in patients with generalized anxiety disorder (GAD).
• 3.Management reiterated timelines for GlyphAllo in MDD, with Ph1 driving simulation data due in 2H26 and Ph2b data in 1H27.

Table of Contents

• Additional Ph1 data validate the Glyph platform and support Ph2 generalized anxiety program
• The Ph2b study of GlyphAllo is underway, with topline results expected in 1H27
• Valuation, model changes and risks